GlobalData on MSN6d
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancerThe FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...
Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab ...
Opdivo plus chemotherapy showed a significant overall survival benefit in resectable NSCLC, per final Phase 3 CheckMate -816 study results. In October, the FDA approved Opdivo for resectable NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback